乙肝新药-话题@MedSci

#乙肝新药#

5篇内容 | 1322人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2250317, encodeId=6735225031e5f, content=<a href='/topic/show?id=3d745346316' target=_blank style='color:#2F92EE;'>#慢性乙型肝炎#</a> <a href='/topic/show?id=2a3f2343353' target=_blank style='color:#2F92EE;'>#乙肝新药#</a>, objectTitle=关键突破 | 乙肝新药临床试验，这几点值得深思！, objectType=article, longId=861709, objectId=85b3861e0955, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/doctor-writing-D3K6QME.jpg, objectUrl=/article/show_article.do?id=85b3861e0955, replyNumber=0, likeNumber=27, createdTime=2025-02-03, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=陕西省, moduleDTOList=[ModuleDTO(moduleId=85b3861e0955, moduleTitle=关键突破 | 乙肝新药临床试验，这几点值得深思！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=85b3861e0955)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2243277, encodeId=0c6122432e707, content=<a href='/topic/show?id=2a3f2343353' target=_blank style='color:#2F92EE;'>#乙肝新药#</a> <a href='/topic/show?id=32f8121890c2' target=_blank style='color:#2F92EE;'>#Xalnesiran#</a>, objectTitle=【新药进展】Xalnesiran联合治疗II期结果发表NEJM：联用聚乙二醇干扰素α组的HBsAg清除率及血清学转换率均最高, objectType=article, longId=855533, objectId=4fda8555336f, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240827/1724750166404_8538692.png, objectUrl=/article/show_article.do?id=4fda8555336f, replyNumber=0, likeNumber=30, createdTime=2024-12-18, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=陕西省, moduleDTOList=[ModuleDTO(moduleId=4fda8555336f, moduleTitle=【新药进展】Xalnesiran联合治疗II期结果发表NEJM：联用聚乙二醇干扰素α组的HBsAg清除率及血清学转换率均最高, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4fda8555336f)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2241399, encodeId=d8412241399ec, content=<a href='/topic/show?id=2a3f2343353' target=_blank style='color:#2F92EE;'>#乙肝新药#</a> <a href='/topic/show?id=4efc120614f7' target=_blank style='color:#2F92EE;'>#AASLD2024#</a>, objectTitle=【AASLD2024速递】PD-L1抑制剂类乙肝新药研究进展汇总, objectType=article, longId=854531, objectId=15b985453105, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240703/1719970229062_92910.png, objectUrl=/article/show_article.do?id=15b985453105, replyNumber=0, likeNumber=33, createdTime=2024-12-08, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=陕西省, moduleDTOList=[ModuleDTO(moduleId=15b985453105, moduleTitle=【AASLD2024速递】PD-L1抑制剂类乙肝新药研究进展汇总, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=15b985453105)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2239623, encodeId=eede223962338, content=<a href='/topic/show?id=2a3f2343353' target=_blank style='color:#2F92EE;'>#乙肝新药#</a> <a href='/topic/show?id=4efc120614f7' target=_blank style='color:#2F92EE;'>#AASLD2024#</a>, objectTitle=【AASLD2024速递】乙肝新药Xalnesiran II期研究48周随访结果公布：获得HBsAg清除后再停用NA更安全, objectType=article, longId=852533, objectId=a746852533e2, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240521/1716259408769_5579292.jpg, objectUrl=/article/show_article.do?id=a746852533e2, replyNumber=0, likeNumber=43, createdTime=2024-11-27, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a746852533e2, moduleTitle=【AASLD2024速递】乙肝新药Xalnesiran II期研究48周随访结果公布：获得HBsAg清除后再停用NA更安全, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a746852533e2)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2212256, encodeId=765c22122562c, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a> <a href='/topic/show?id=2a3f2343353' target=_blank style='color:#2F92EE;'>#乙肝新药#</a> <a href='/topic/show?id=458210328bf' target=_blank style='color:#2F92EE;'>#JNJ-3989#</a> <a href='/topic/show?id=40a21153043b' target=_blank style='color:#2F92EE;'>#EASL2024#</a>, objectTitle=【EASL2024速递】乙肝新药JNJ-3989研究进展汇总, objectType=article, longId=828911, objectId=e1d1828911a8, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240625/1719326958545_5579292.jpg, objectUrl=/article/show_article.do?id=e1d1828911a8, replyNumber=0, likeNumber=137, createdTime=2024-06-28, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=e1d1828911a8, moduleTitle=【EASL2024速递】乙肝新药JNJ-3989研究进展汇总, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e1d1828911a8)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2036332, encodeId=d918203633264, content=<a href='/topic/show?id=2a3f2343353' target=_blank style='color:#2F92EE;'>#乙肝新药#</a>, objectTitle=豪森药业1类乙肝新药「艾美酚胺替诺福韦片」申报上市，拟优先审评, objectType=article, longId=200943, objectId=904a20094367, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=904a20094367, replyNumber=0, likeNumber=93, createdTime=2021-02-27, rootId=0, userName=charl1234567, userId=62a7397, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=904a20094367, moduleTitle=豪森药业1类乙肝新药「艾美酚胺替诺福韦片」申报上市，拟优先审评, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=904a20094367)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2036331, encodeId=16c92036331b3, content=<a href='/topic/show?id=2a3f2343353' target=_blank style='color:#2F92EE;'>#乙肝新药#</a>, objectTitle=五年来乙肝新药上市，专家：价格是影响新药可及性关键, objectType=article, longId=155500, objectId=62e415550039, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=62e415550039, replyNumber=0, likeNumber=70, createdTime=2019-01-06, rootId=0, userName=charl1234567, userId=62a7397, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=62e415550039, moduleTitle=五年来乙肝新药上市，专家：价格是影响新药可及性关键, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=62e415550039)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2036330, encodeId=50d92036330ad, content=<a href='/topic/show?id=2a3f2343353' target=_blank style='color:#2F92EE;'>#乙肝新药#</a>, objectTitle=Sci Trans Med：乙肝新药进入临床阶段，有望彻底治愈乙肝, objectType=article, longId=119187, objectId=5dab11918e83, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5dab11918e83, replyNumber=0, likeNumber=72, createdTime=2018-06-30, rootId=0, userName=charl1234567, userId=62a7397, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5dab11918e83, moduleTitle=Sci Trans Med：乙肝新药进入临床阶段，有望彻底治愈乙肝, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5dab11918e83)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2036329, encodeId=ba972036329af, content=<a href='/topic/show?id=2a3f2343353' target=_blank style='color:#2F92EE;'>#乙肝新药#</a>, objectTitle=PLoS One：乙肝新药2a期临床出色，有望带来功能性治愈, objectType=article, longId=99655, objectId=c2099965505, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c2099965505, replyNumber=0, likeNumber=109, createdTime=2017-11-22, rootId=0, userName=charl1234567, userId=62a7397, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c2099965505, moduleTitle=PLoS One：乙肝新药2a期临床出色，有望带来功能性治愈, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c2099965505)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2036328, encodeId=0e1c203632852, content=<a href='/topic/show?id=2a3f2343353' target=_blank style='color:#2F92EE;'>#乙肝新药#</a>, objectTitle=福音：FDA批准功能性治愈乙肝新药ARC-520的临床研究, objectType=article, longId=49573, objectId=0bae495e376, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0bae495e376, replyNumber=0, likeNumber=84, createdTime=2015-07-12, rootId=0, userName=charl1234567, userId=62a7397, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0bae495e376, moduleTitle=福音：FDA批准功能性治愈乙肝新药ARC-520的临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0bae495e376)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

乙肝新药

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#慢性乙型肝炎# #乙肝新药#

关键突破 | 乙肝新药临床试验，这几点值得深思！

2025-02-03发表于陕西省

梅斯管理员 (审核中...)

前往app查看评论内容

#乙肝新药# #Xalnesiran#

【新药进展】Xalnesiran联合治疗II期结果发表NEJM：联用聚乙二醇干扰素α组的HBsAg清除率及血清学转换率均最高

2024-12-18发表于陕西省

梅斯管理员 (审核中...)

前往app查看评论内容

#乙肝新药# #AASLD2024#

【AASLD2024速递】PD-L1抑制剂类乙肝新药研究进展汇总

2024-12-08发表于陕西省

梅斯管理员 (审核中...)

前往app查看评论内容

#乙肝新药# #AASLD2024#

【AASLD2024速递】乙肝新药Xalnesiran II期研究48周随访结果公布：获得HBsAg清除后再停用NA更安全

2024-11-27

梅斯管理员 (审核中...)

前往app查看评论内容

#联合治疗# #乙肝新药# #JNJ-3989# #EASL2024#

【EASL2024速递】乙肝新药JNJ-3989研究进展汇总

2024-06-28发表于上海

charl1234567 (审核中...)

前往app查看评论内容

#乙肝新药#

豪森药业1类乙肝新药「艾美酚胺替诺福韦片」申报上市，拟优先审评

2021-02-27

charl1234567 (审核中...)

前往app查看评论内容

#乙肝新药#

五年来乙肝新药上市，专家：价格是影响新药可及性关键

2019-01-06

charl1234567 (审核中...)

前往app查看评论内容

#乙肝新药#

Sci Trans Med：乙肝新药进入临床阶段，有望彻底治愈乙肝

2018-06-30

charl1234567 (审核中...)

前往app查看评论内容

#乙肝新药#

PLoS One：乙肝新药2a期临床出色，有望带来功能性治愈

2017-11-22

charl1234567 (审核中...)

前往app查看评论内容

#乙肝新药#

福音：FDA批准功能性治愈乙肝新药ARC-520的临床研究

2015-07-12

科室
- - 订阅+
  - 更多科室
工具
服务